Looking to fill a treatment gap, the U.S. Biomedical Advanced Research and Development Authority (BARDA) is launching the first stage of a $100 million prize competition to support development of broad-spectrum, small-molecule antiviral therapies targeting viruses in the Togaviridae and Flaviviridae families.
Looking to fill a treatment gap, the U.S. Biomedical Advanced Research and Development Authority (BARDA) is launching the first stage of a $100 million prize competition to support development of broad-spectrum, small-molecule antiviral therapies targeting viruses in the Togaviridae and Flaviviridae families.
NIH researchers report that in severe influenza, survival improves at late stages only when antivirals are combined with therapies that repair lung damage or limit harmful T-cell responses, explaining why anti-inflammatory treatments alone are often ineffective.
NIH researchers report that in severe influenza, survival improves at late stages only when antivirals are combined with therapies that repair lung damage or limit harmful T-cell responses, explaining why anti-inflammatory treatments alone are often ineffective.
Aligos Therapeutics Inc. and Katholieke Universiteit Leuven (KU Leuken) have synthesized antiviral compounds reported to be useful for the treatment of coronavirus acute respiratory syndrome, norovirus and picornavirus infections.
Adaptor protein-2 associated kinase 1 (AAK1) is key in clathrin-mediated endocytosis, which diverse viruses hijack in order to infect cells. Inhibiting AAK1 has been shown to block the entry of hepatitis C, dengue and rabies viruses into cells.
Human rhinovirus (HRV) is the most frequent cause of upper respiratory infections and a key trigger of asthma exacerbations. No effective anti-HRV therapies exist, and vaccine efforts have been unsuccessful due to its extreme genetic and antigenic diversity, with over 160 known serotypes.
Researchers from the CUNY Advanced Science Research Center and their collaborators recently published a paper in Science Advances on Aug. 27, 2025, about synthetic carbohydrate receptors (SCRs) and their potential as broad-spectrum antivirals by targeting the viral envelope N-glycans. They described the antiviral activity of a series of tetrapodal SCRs both in vitro and in vivo, showing their potential as broad-spectrum inhibitors of viral infection.
The COVID-19 pandemic sent the world into a tailspin, raising ongoing concerns about biosecurity, a subject that encompassed the better part of the morning June 16, the first day of the Biotechnology Innovation Organization’s annual conference in Boston.
